CIPLA LTD vs Dr.Datsons Labs Ltd

A side-by-side comparison of CIPLA LTD (CIPLA) and Dr.Datsons Labs Ltd (DRDATSONS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads CIPLA vs DRDATSONS on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth· not comparable
  • Size & financial health31

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.42
P/E ratio
0.00
3.42
P/B ratio
0.00
0.92%
Dividend yield
0.00%
₹48.02
EPS
₹0.21

Profitability

CIPLA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
0.19%
15.00%
Return on capital
5.00%
21.00%
EBITDA margin
14.00%
13.71%
Net margin
0.24%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y) even
10.88%
Profit CAGR (3Y) even

Size & financial health

CIPLA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.14L Cr
Market cap
₹0 Cr
₹28,163 Cr
Revenue
₹421 Cr
₹3,862 Cr
Net profit
₹1 Cr
0.00
Debt / equity
0.00
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
Dr.Datsons Labs Ltd
  • + ["Company has reduced debt.", "Stock is trading at 0.13 times its book value"]
  • ["Company has low interest coverage ratio.", "Company has a low return on equity of 9.06% over last 3 years.", "Earnings include an other income of Rs.17.1 Cr.", "Dividend payout has been low at 8.42% of profits over last 3 years", "Company has high debtors of 317 days."]
CIPLA LTD full analysis Dr.Datsons Labs Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.